CQN-PHENOM
8.10.2021 04:02:09 CEST | Business Wire | Press release
Fourth paragraph, first sentence of release dated October 6, 2021, should read: As the vice president and general manager for Phenom in Central Europe, Gerstner will be responsible for strengthening existing and new customer relationships in Central Europe, including Germany, Austria, Switzerland, France and BENELUX (instead of in Germany, Austria and Switzerland).
The updated release reads:
PHENOM HIRES SENIOR LEADERS TO OVERSEE RAPID GROWTH IN EUROPE
Thomas Gerstner and Andy Joeres bring decades of experience scaling SaaS enterprises in EMEA
Phenom , the global leader in Talent Experience Management (TXM), today announced the hiring of two executives to drive the company’s surging global growth. Thomas Gerstner will lead Phenom’s business in Central Europe, and Andy Joeres will oversee initiatives in the United Kingdom and Ireland, Northern Europe, Middle East and Africa. The positions were created to continue building momentum in EMEA, where there has been an exploding demand for talent experience, AI and automation from HR teams.
Following numerous acquisitions and the addition of many enterprise customers in EMEA, Phenom’s headcount in Europe has quickly exceeded 100 employees. With operations in the United Kingdom, Ireland, Germany, Netherlands, France, Italy, Spain, Sweden, and Switzerland, Phenom expects to continue aggressively recruiting into 2022 across customer success, sales, account management, marketing, engineering, product and more.
“The need for AI-powered talent experiences is universal, and the interest in Phenom’s platform originating from EMEA is increasing every day,” said Mahe Bayireddi, co-founder and CEO of Phenom. “We’re thrilled that Andy and Thomas are joining our team. They carry proven track records of success meeting ambitious business objectives in many different markets around the world, and we expect their leadership will inspire our talented overseas team to bring amazing talent experiences to global enterprises.”
As the vice president and general manager for Phenom in Central Europe, Gerstner will be responsible for strengthening existing and new customer relationships in Central Europe, including Germany, Austria, Switzerland, France and BENELUX. In his last role, he was the EMEA president of Pathlock — defining, implementing, and executing growth strategy across all channels. For 14 years, Gerstner also held various senior executive roles at SAP, including senior vice president for the SuccessFactors business in the Middle and Eastern European region and managing director in Asia.
“Phenom is already turning heads in Central Europe, and it’s incredible to now be part of this special journey,” said Gerstner. “Organisations that have invested in AI-powered talent experiences are miles ahead of their competitors. Already in Central Europe, Phenom’s sophisticated platform is making a huge difference, helping organizations transform the way they acquire, develop and retain talent.”
Joeres will serve as Phenom’s vice president of sales for EMEA, where he will focus on bringing new business to the company. Joeres has managed the launch of hyper-growth initiatives for companies like Celonis and Snow, where he spearheaded triple-digit, year-over-year growth and exponentially scaled personnel from small teams to large units with deep impact across the enterprise.
“My passion has always been designing go-to-market strategies and then executing them for companies that have a clear, profound vision,” said Joeres. “HR teams are realizing that intelligent experiences are the present and future of hiring and retaining the best talent — and the Phenom TXM platform is the solution. AI and automation are now requirements for scaling those experiences. I look forward to championing Phenom’s platform to help organisations reduce cost and time to hire, while increasing employee retention.”
About Phenom
Phenom is a global HR technology company with a purpose to help a billion people find the right job. With an expertise in building AI-powered, scalable solutions, Phenom Talent Experience Management (TXM) personalizes and automates the talent journey for candidates, recruiters, employees and management with its Career Site, Chatbot, CRM, CMS, SMS and Email Campaigns, University Recruiting, Internal Mobility, Career Pathing, Diversity & Inclusion, Talent Marketplace, Gigs, Referrals, Hiring Manager and Analytics. As a result, employers improve their talent acquisition and talent management efforts by helping candidates and employees find the right job, recruiters identify and engage the right talent, and management optimizes HR strategy, process and spend. Phenom was ranked among the fastest-growing technology companies in the 2020 Deloitte Technology Fast 500, and won a regional 2020 Timmy Award for launching and optimizing HelpOneBillion.com.
Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
For more information, please visit www.phenom.com . Connect with Phenom on LinkedIn , Twitter , Facebook , YouTube and Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211006005383/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
